Could a new drug help preserve insulin production in type 1 diabetes?

NCT ID NCT05574335

Terminated Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested four different doses of siplizumab in 8 people aged 8–45 who were diagnosed with type 1 diabetes within the past 18 months. The goal was to find a safe dose that changes certain immune cell patterns linked to better insulin production. Participants received weekly infusions for 12 weeks and were followed for up to a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: siplizumab (TCD 601)
What this could lead to: If successful, this study could identify a siplizumab dosing regimen that helps preserve the body's ability to produce insulin in people newly diagnosed with type 1 diabetes.
What could go wrong: This is a very early, small trial (only 8 participants) that was terminated, so results are limited. The drug may not show meaningful benefit or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES MELLITUS

Contacts and locations

Show contact details

Locations

Benaroya Research Institute at Virginia Mason: Diabetes Research Program

Seattle, Washington, 98101, United States
Columbia University Medical Center: Naomi Berrie Diabetes Center

New York, New York, 10032, United States
University of Colorado School of Medicine: Barbara Davis Center for Diabetes

Aurora, Colorado, 80045, United States
University of Iowa Children's Hospital: Department of Pediatrics, Pediatric Endocrinology and Diabetes

Iowa City, Iowa, 52242, United States
University of Texas Southwestern Medical Center: Department of Internal Medicine, Division of Endocrinology

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.